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ALS-Linked SOD1 Mutant G85R Mediates Damage
to Astrocytes and Promotes Rapidly Progressive
Disease with SOD1-Containing Inclusions
L. I. Bruijn,1 M. W. Becher,3,6 M. K. Lee,3,6 role in regulation of oxidative stress and protection
K. L. Anderson,1 N. A. Jenkins,7 N. G. Copeland,7 against oxygen radical-induced cellular damage (Halli-
S. S. Sisodia,3,5,6 J. D. Rothstein,4 D. R. Borchelt,3,6 well, 1994; Yu, 1994), an initially attractive hypothesis
D. L. Price,3,5,6 and D. W. Cleveland,1,2 was that SOD1-linked familial ALS resulted from free
1Ludwig Institute for Cancer Research radical damage caused by diminished superoxide scav-
2Departments of Medicine and Neuroscience enging activity (Bowling et al., 1993; Deng et al., 1993).
University of California at San Diego Consistent with this idea were reductions (50%–60%)
La Jolla, California 92093 of dismutase activity in red blood cells, lymphocytes,
3Department of Pathology and brain from individuals with familial ALS mutations
4Department of Neurology (Bowling et al., 1993; Deng et al., 1993; Robberecht et
5Department of Neuroscience al., 1994) and the observation that reductions in SOD1
6Laboratory of Neuropathology activity were associated with death of neurons in several
Johns Hopkins University School of Medicine culture systems (Rothstein et al., 1994a; Greenlund et
Baltimore, Maryland 21205 al., 1995).
7Mammalian Genetics Laboratory Despite this early focus on loss of activity as themech-
Advanced Bioscience Laboratories Research Program anism underlying human disease, subsequent in vitro
National Cancer Institute studies demonstrated that familial ALS mutations vary
Frederick, Maryland 21701 in their effects on enzymatic activity and, at least in
some instances (such as the substitution of arginine for
glycine at position 37 [G37R]), the mutant enzyme re-
Summary tains full specific activity (Borchelt et al., 1994). In lym-
phocytes from individuals with familial ALS, there is only
High levels of familial Amyotrophic Lateral Sclerosis a modest reduction in the abundance of the G37R SOD1
(ALS)-linked SOD1 mutants G93A and G37R were pre- polypeptide, and the mutant polypeptide is fully active
viously shown to mediate disease in mice through an (Borchelt et al., 1994). Moreover, SOD1 null mice live to
acquired toxic property. We report here that even low adulthood and to date have not been documented to
levels of another mutant, G85R, cause motor neuron develop motor neuron disease (Reaume et al., 1996).
disease characterized by an extremely rapid clinical Finally and most convincingly, lines of transgenic mice
progression, without changes in SOD1 activity. Initial expressing either G93A or G37R human SOD1 have ele-
indicators of disease are astrocytic inclusions that vated SOD1 activity levels (4- to 14-fold that of non-
stain intensely with SOD1 antibodies and ubiquitin and transgenic littermates) and develop progressive hind-
SOD1-containing aggregates in motor neurons, fea-
limb weakness and muscle wasting between 4 and 6
tures common with some cases of SOD1 mutant-
months of age. In these animals, motor neurons degen-mediated ALS. Astrocytic inclusions escalate mark-
erate, often exhibiting vacuoles that have been inter-edly as disease progresses, concomitant with a
preted to originate from theGolgi and endoplasmic retic-decrease in the glial glutamate transporter (GLT-1).
ulum in cell bodies of G93A mice (Dal Canto and Gurney,Thus, the G85R SOD1 mutant mediates direct damage
1994) and from degenerating mitochondria in dendritesto astrocytes, which may promote the nearly synchro-
or axons of G37R mice (Wong et al., 1995). Disease innous degeneration of motor neurons.
G93A and G37R mice requires high levels of mutant
SOD1. In addition, one line of mice expressing a muta-
tion in mouse SOD1 that is homologous in position to theIntroduction
familial ALS-linked G85R mutation has been reported
to cause motor neuron loss and rapidly progressingAmyotrophic Lateral Sclerosis (ALS) is a progressive
disease without elevating SOD1 activity (Ripps et al.,neurodegenerative disorder resulting from degeneration
1995).and death of lower motor neurons in the brain stem
In this report, we document that human SOD1 mutantand spinal cord, leading to generalized weakness and
G85R can cause dominantly inherited, rapidly progres-muscle atrophy (Delisle and Carpenter, 1984; Banker,
sive disease in spite of accumulation to very low levels1986). Of ALS cases, 5%–10% are familial, inherited
in mice (0.2–1.0 3 endogenous mouse SOD1) and with-in an autosomal dominant manner. The mechanisms
out any increase or decrease in overall SOD1 activity.leading to degeneration of motor neurons in familial and
Despite latencies of .8 months, once initiated, motorsporadic ALS are not clearly understood. The discovery
neuron loss proceeds nearly synchronously with z40%(Rosen et al., 1993) of dominant, missense mutations
of large spinal motor neuron axons degenerating over(.45 such mutations are now known) in the metalloen-
a 2 week disease duration. Moreover, prominent SOD1-zyme Cu–Zn superoxide dismutase (SOD1) as the pri-
containing inclusions in astrocytes appear prior to clini-mary cause of 15%–20% of familial ALS cases has fo-
cal signs and increase markedly in abundance duringcused attention on how mutants in this ubiquitously
disease progression, implicating astrocytes as primaryexpressed enzyme cause selective death of motor neu-
rons. Because SOD1 activity is believed to play a crucial targets for mutant-SOD1 mediated damage. Moreover,
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the glial glutamate transporter (GLT-1), the major gluta- Table 1. Disease Progression in G85R SOD1 Mice (Line 148)
mate transporter in spinal cord, decreases during dis-
Astroglial
ease progression, implicating glutamate mediated exci- Astrocytosis 2 2 2 2 1 1 111
totoxicity as a mechanism to account for the nearly SOD1–immunoreactive
synchronous degeneration of motor neurons. inclusions 2 2 2 1 2 11 111
Ubiquitin–immunoreactive
inclusions 2 2 2 1 2 11 111Results
Neuronal
Neuronal loss 2 2 2 2 2 2 11Low Levels of G85R Protein Accumulate
Axonal degeneration 2 2 2 2 1 11 111in Spinal Cords of Transgenic Mice
SOD1 and ubiquitin–with Motor Neuron Disease
immunoreactive inclusions 2 2 2 2 2 1 11
Transgenic mice were generated that carry a 12kb geno- SOD1-immunoreactive
mic DNA fragment encodinga human FALS-linked SOD1 perikaryal aggregates 2 2 2 1 1 1 1
Ubiquitin–immunoreactivepoint mutation (Rosen et al, 1993) converting codon 85
perikaryal aggregates 2 2 2 1 1 1 1from glycine to arginine (G85R; Figure 1A). From 242
Clinical phenotype 2 2 2 2 2 disease endpotential transgenic pups, 48 founders were identified
onset stagewith the G85R mutant transgene.Lines were established
Age in months 2 3.5 5.5 6 6.5 7.5 8for eight founders with low, medium, and high copy
numbers (between 2 and 15 copies) as determined by Spinal cords of animals at various ages were carefully examined for
severity of ventral root degeneration, neuronal or glial inclusions;tail DNA blots.
SOD and ubiquitin immunoreactivity and astrocytosis were as-To determine the level of the human G85R mutant
sessed and graded as follows: 1, mild degree or infrequent occur-SOD1 that accumulated in each of the transgenic lines,
rence; 11, moderate density or moderate occurrence; and 111,spinal cord extracts were immunoblotted along with a
marked degree and frequent.
series of known amounts of purified human erythrocyte
SOD1 (Figures 1B and 1C, lanes 1–4). The amount of
G85R mutant was determined using an anti-peptide
with endogenous SOD1, whereas accumulated levels ofpolyclonal antibody specific for human SOD1 (Figure
mutant protein in cortex, brain stem, and cerebellum are1C), which does not bind to mouse SOD1 in extracts
lower than endogenous mouse SOD1. A similar assay offrom normal mice (Figure 1C, lane 5). Total SOD1 (Figure
red blood cell lysates (Figure 2B, lanes 1–6) revealed1B, lanes 5–13) was measured using a polyclonal anti-
that G85R SOD1 was undetectable in red blood cellsbody generated against a peptide identical in mouse
(Figure 2B, lanes 2–4), whereas high levels of humanand human SOD1. Phosphorimaging of these and a set
SOD1 were present in transgenic mice expressing wild-of parallel blots (analyzing samples from four animals
type or G37R mutant SOD1 (e.g., 4 3 the endogenouseach for lines 148, 164, and 87 and two animals for
SOD1 level in mice expressing wild-type human SOD1;each of the other lines) revealed that mutant SOD1 in
Figure 2B, lane 1). Analysis of the levels of the endoge-transgenic lines (lanes 6–13) accumulated to 0.02% of
nous and G85R mutant SOD1 in spinal cords from linetotal protein (z20% of endogenous mouse SOD1) for
148 revealed that levels of mutant SOD1 were un-the lowest expressing line (line 46; Figure 1C, lane 11)
changed at 1 and 3 months of age but were elevatedand 0.1% of total protein (equivalent to mouse SOD1)
by 2-fold at end-stage disease, whereas levels of endog-in the highest expressing line (line 148, Figure 1C, lane
enous mouse SOD1 were unaltered in these G85R9). Using an antibody specific for mouse SOD1, levels
transgenics (Figure 2C, middle lane) and in non-of endogenous mouse SOD1 were unchanged in all lines
transgenic littermates (Figure 2C, bottom lane). While(compare normal mouse in Figure 1D, lane 5 with
we cannot exclude a potential contribution of increasedtransgenic mice in Figure 1D, lanes 6–13).
RNA transcriptionor RNA stability to the increased levelsRNA blotting for levels of transgene-encoded RNA
of G85R at end stage, these data strongly suggest that(not shown) revealed a level of RNA in the highest G85R
degradation of mutant G85R SOD1 is slowed as theexpressing line (line 148; Figure 1C, lane 9), indistin-
animals age.guishable from that in a mouse line previously reported
to accumulate FALS-linked mutant G37R to 5 3 the level
G85R SOD1 Does Not Influence Overallof mouse SOD1 (Wong et al., 1995). The lower level of
SOD1 Activityaccumulated G85R (relative to that of G37R in mice with
To test whether theG85R mutantaffects levels of activitycomparable levels of mutant encoding SOD1 mRNAs)
of the endogenous SOD1 subunits, spinal cord extractsconfirms in a more in vivo context the finding from trans-
were electrophoresed in native gels, and activity wasfection experiments with cultured cells (Borchelt et al.,
measuredby theability of SOD1 to inhibit theconversion1995) that the G85R polypeptide has a shorter half life
of nitro blue tetrazolium to formazan. In three mice fromthan G37R.
line 148, SOD1 activity was similar to that in a controlImmunoblotting of extracts of various tissues, includ-
animal (compare Figure 2D, lanes 5–7 with lane 4). Sinceing spinal cord, cortex, brain stem, cerebellum, muscle,
the G85R subunit has previously been shown to be com-liver, and kidney (Figure 2A), revealed that G85R accu-
pletely inactive in this gel assay (Borchelt et al., 1994),mulated in all these tissues, as seen earlier for mutant
the constant level of activity indicates that activity ofG37R (Wong et al., 1995). Using an antibody recognizing
the endogenous mouse SOD1 was not altered, consis-human and mouse SOD1 (Figure 2A), mutant SOD1 ac-
cumulates in both kidney and liver to levels comparable tent with the constant level of mouse SOD1 polypeptide
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Figure 1. Low Levels of Mutant G85R SOD1
Cause Motor Neuron Disease in Multiple
Lines of Transgenic Mice
(A) Schematic representation of the human
SOD1 gene showing the conversion of gly-
cine (GGC) to arginine (CGC) at codon 85 in
exon 4.
(B–D) Total protein (70 mg) extracted from spi-
nalcords of eight transgenic lines (lanes 6–13)
and a nontransgenic littermate (lane 5) were
electrophoresed on 15% SDS–PAGE gels
and immunoblotted using rabbit polyclonal
antibodies that recognize (B) a common epi-
tope shared between human and mouse
SOD1, (C) an epitope on human but not
mouse SOD1, or (D) an epitope specific for
mouse SOD1. All antibodies were detected
with 125I-labeled protein A. A series of 2-fold
dilutions of purified human SOD1 was immu-
noblotted in parallel (lanes 1–4) to provide
quantitation standards.
(E) Levels of G85R mutant SOD1 versus en-
dogenous wild-type mouse SOD1 deter-
mined by phosphorimaging of the blots in (B)
and (C).
(F) Aberrant hindlimb posture developed
within 3 days of clinical onset in transgenic
mice from G85R line 148. Arrows point to ob-
viously abnormal hindlimbs.
(Figure 1D) and the observation that mutant SOD1 does developed hindlimb paralysis and muscle atrophy (Table
1; Figure 1F). The age of onset varied between 8–10not exert a dominant negative effect in vitro (Borchelt
et al., 1995). The G85R polypeptide retains some activity months for the highest expressing line (line 148–G85R
levels 100% of endogenous SOD1) and 12–14 monthsin vivo (as reported for the mutant protein assayed in
solution after expression with a baculovirus vector [Fujii for the lowest expressing line (line 74–G85R levels 20%
of endogenous SOD1), but after onset, all mutant lineset al., 1995] or in yeast (Corson et al., unpublished data]),
but even if fully active in vivo, its low abundance cannot showed a uniformly rapid progression of disease. The
initial sign was weakened grip strength in one hindlimb,raise overall SOD1 activity significantly over that in non-
transgenic control mice. Although protein levels of mu- which spread very rapidly to the other hindlimb and then
to the forelimbs. Mice were completely paralyzed withintant SOD1 increase at end-stage disease (Figure 2C),
endogenous mouse SOD1 activity in transgenic mice is 2 weeks after initial signs. In a few mice, disease ad-
vanced so rapidly that hind- and forelimbs appearednot altered with age (compare Figure 2D, lanes 5–7 and
9–11 for transgenic animals with similar samples from affected simultaneously. In some animals, the hindlimbs
were so severely affected that the mice were unable tocontrol mice in lanes 4 and 8).
feed (Figure 1F) and were sacrificed before any signs
of forelimb involvement. One line (line 46) expressingG85R SOD1 Causes a Late-Onset, Rapidly
Progressive Motor Neuron Disease the lowest level of mutant SOD1 (Figure 1C, lane 11) did
not develop clinical signs by 15 months.Each of the eight lines of G85R mice was examined at
different ages for clinical signs. In seven lines, mice Ten animals in line 148 were closely observed from
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the timeof theearliest obvious clinical signs. In all cases,
within 2–3 days after appearance of hindlimb weakness,
the affected hindlimb became severely paralyzed, and
the limb assumed a distorted posture (Figure 1F). Within
3–4 days, the other hindlimb displayed obvious weak-
ness, and 1–2 weeks after onset, these animals were so
severely immobilized that they were unable to feed.
Evolution of Pathology: The Earliest Lesions Are
SOD1-Containing Inclusions in Astrocytes and
More Diffuse SOD1/Ubiquitin-Containing
Aggregates in Motor Neurons
To delineate the evolution of pathology, we examined
spinal cords from G85R SOD1 mice (line 148) that de-
velop clinical signs between 8–10 months of age. No
abnormalities were identified in mice ,6 months of age.
However, at 6 months (Table 1), early abnormalities of
two types were identified.
First, round inclusions with a dense core and a clear
peripheral halo were revealed by hemotoxylin and eosin
(H and E) staining (Figure 3B). These inclusions resemble
the Lewy bodies that are present in the cytoplasm of
pigmented neurons in the substantia nigra and locus
ceruleus in Parkinson’s disease (Galloway et al., 1996),
but in the G85R mice, these initial “Lewy body-like”
inclusions were in astrocytes, not neurons, as indicated
by immunoreactivy with antibodies to the astrocyte-spe-
cific glial fibrillary acidic protein (GFAP) (Figure 3A). In-
clusions in astrocytes became more abundant as dis-
ease progressed. By end stage (Figure 3C), when SOD1
increased 2-fold in spinal cordextracts (Figure2C), there
was a marked increase in astrocytosis (Figure 3C, open
arrow) and a z10-fold increase in inclusions. Almost all
of these were confirmed by staining with antibodies to
GFAP (Figure 3C) and absence of staining with neurofila-
ment antibodies (Figures 3D and 3E, arrows) to be within
astrocytes. Similar astroglial inclusions were prominent
not only in line 148 but also in three other G85R lines
examined in detail (lines 103, 164, and 87). A striking
finding was that throughout disease, both core and pe-
riphery of inclusions (Figure 3F) were highly immunore-
active with an antibody recognizing a common epitope
in human and mouse SOD1 (Figure 3G, inset). Only the
periphery of these inclusions (both in young animals
or at end stage) was immunoreactive for GFAP (Figures
3A and 3C) or ubiquitin (Figure 3F, inset) antibodies.
SOD1-immunoreactive inclusions were also observedFigure 2. G85R SOD1 Accumulates in a Variety of Tissues, with a
in smaller cells in the white matter, which showed oligo-2-Fold Increase in Spinal Cord at End-Stage Disease
dendrocytic features and lacked GFAP (not shown).(A) Total protein (70 mg) from various tissues from a 3-month-old
G85R SOD1 transgenic mouse (line 148) was immunoblotted with Electron microscopy of inclusions in cell bodies (Figure
a rabbit polyclonal antibody recognizing an epitope (top lane) spe- 4A) revealed that the core consisted of a heterogeneous
cific for human SOD1 or (bottomlane) recognizing mouse andhuman mass of short (200–300 nm long), disorganized filamen-
SOD1.
tous material covered with small granules (z20 nm in(B) Immunoblots with an antibody specific for human SOD1 of ex-
diameter; Figures 4B and 4C) in which organelles weretracts from red blood cells from a mouse transgenic for (lane 1)
entrapped, with a less dense and in some cases linearwild-type human SOD1, (lanes 2–4) G85R lines 148 (3 months old),
148 (10 months old), and 124 (10 months old), respectively, and
(lanes 5 and 6) nontransgenic control mice. A series of 2-fold dilu-
tions of purified human SOD1 were immunoblotted in parallel (lanes
7–10) to provide standards for quantitation. (D) SOD1 activity in spinal cord extracts from 3- (lanes 4–7) and 10-
(C) Total protein extracts from spinal cords of 1-, 3-, and 10-month- (lanes 8–11) month-old transgenic (lanes 5–7 and 9–11) and control
old (top and middle lanes) G85R, line 148 mice and (bottom lane) (lanes 4 and 8) mice determined on native gels (as described by
nontransgenic, control mice immunoblotted with antibodies recog- Beauchamp and Fridovich, 1971). Lanes 1–3: a 2-fold dilution series
nizing an epitope specific for (top lane) human SOD1 or (middle and (0.5, 1, and 2 mg) of human erythrocyte SOD1 used as quantitation
bottom lanes) mouse SOD1. standards.
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array of filaments (z10 nm in diameter) at the periphery undergoing degeneration in ventral roots from animals
before (Figure 6C), at (Figure 6D), and after (Figure 6E)of the inclusion. The absence of reactivity to GFAP anti-
bodies except at the periphery (Figures 3A and 3C) and appearance of clinical signs. Consistent with the earliest
abnormalities in the spinal cord, no significant loss ofthe circumferential GFAP filaments observable at the
edges of these aggregates strongly suggest that GFAP axons was detectable prior to clinical onset (Figures 6A
and 6C), although a small number (,1%) of large (.5is not a major constituent of the filamentous material in
the central domain of these aggregates. mm in diameter) axons in motor roots showed degenera-
tion at 6.5 months (coincident with the earliest spinalA second type of abnormality appearing prior to clini-
cal onset was the presence in a small number of motor cord pathology). However, at the time of the first clinical
signs, 25% of the large motor axons were missing (Fig-neurons of a few diffuse aggregates that were intensely
immunoreactive both for SOD1 (Figure 5B) and ubiquitin ure 6A), and of the surviving axons, 10% were actively
undergoing degeneration (Figure 6B; see also Figure 6D,(Figure 5A), despitenormal appearance by H and E stain-
ing. In contrast, the large majority of neurons as well as arrows). By the end of the 2 week clinical course, about
two thirds of the large axons were absent, while 50% ofnontransgenic neurons and all neurons of G85R animals
at younger ages were unreactive with ubiquitin antibod- those remaining were degenerating (Figure 6B). Smaller
caliber axons (,5 mm in diameter) were not affected aties, and these normal neurons displayed much less in-
tense, diffuse, granular SOD1 immunoreactivity (Figure any stage of the disease (Figure 6A). Analysis of sensory
axons in the dorsal root revealed that prior to clinical5B, arrowheads), as previously reported (Pardo et al.,
1995). Abnormalities in motor neurons progressed from onset, sensory axons were unaffected, whereas at on-
set, 2.5% of large axons (.5 mm in diameter) were ac-diffusely localized SOD1- and ubiquitin-containing ag-
gregates seen prior to clinical onset (Figures 5A and tively degenerating or lost, with a few large swollen ax-
ons (z25 mm in diameter). The number of dorsal root5B) to rounded (Lewy body-like) or irregular inclusions
visible by H and E staining in cell bodies (Figure 5C, axons either dying or lost increased to 7.5% of large
axons at end stage.inset). At end stage, even larger inclusions could be
found in a few neurons both in the cell bodies (Figure
5E) and in proximal axonal processes (Figures 5C and
Selective Loss of the Major Spinal Glutamate5G). Like those in astrocytes, inclusions in neuronal cell
Transporter (GLT-1) during Diseasebodies and swellings of proximal processes displayed
Progression in G85R Miceintense SOD1-immunoreactivity (Figure 5D), both in the
Excitotoxicity from excessive extracellular glutamatecentral core and periphery. In addition, the periphery,
has been proposed as a factor in sporadic ALS, anbut not the central domain, of each inclusion stained
hypothesis arising from demonstration of increased ce-with antibodies to ubiquitin (Figure 5F). Immunocyto-
rebrospinal fluid concentrations of glutamate early inchemistry with antibodies to multiple neurofilament epi-
the clinical course of ALS (Rothstein et al., 1990) andtopes (SMI-31, SMI-32, NF-H [not shown] and NF-L [Fig-
decreased glutamate transport in patients with sporadicure 5H]) revealed that neurofilaments were excluded
ALS (Rothstein et al., 1992). Inactivation of glutamate isfrom all of these inclusions and swellings but were often
accomplished by its removal from extracellular spacefound circumferentially around an inclusion. Vacuoles
by glutamate transporters, three of which have beenlike those in cell bodies, dendrites, and axons of pre-
identified: GLT-1 (Pines et al., 1992) and GLAST (Storckviously reported transgenic mice expressing SOD1 mu-
et al., 1992) found in glia (Rothstein et al., 1994b) andtants G93A (Gurney et al., 1994) or G37R (Wong et al.,
EAAC1 (Kanai et al., 1993) found only in neurons1995) were not seen at any point in disease, and mito-
(Rothstein et al., 1994b). To examine if diminished abilitychondria appeared morphologically normal. Compari-
to sequester glutamate could be contributing to theson of spinal cord sections of nontransgenic control and
rapid progression of G85R-mediated disease, we immu-end-stage G85R animals revealed obvious loss of motor
noblotted spinal cord homogenates from nontransgenicneurons in the ventral horn as the result of mutant SOD1
and G85R mice and measured each transporter withexpression (not shown).
specific antibodies (Rothstein et al., 1994b). In four outNeuronal abnormalities were not limited to the ventral
of four animals examined, there was a 50% decreasemotor neuron populations but included small neurons
in levels of the GLT-1 protein in spinal cord extractsnear thecentral canal and rare interneurons of the dorsal
from end-stage G85R mice (analyses of two of thesehorns. Studies, to be reported in detail elsewhere, of
animals are presented in Figure 7B, lane 4) comparedthe remainder of the central nervous system revealed
to G85R mice at 3 months (Figure 7B, lane 3). Levelssimilar-appearing eosinophilic inclusions in brain stem
of GLT-1 were constant in age-matched control miceneurons and astrocytes, most prominently in the pons.
(Figure 7, lanes 1 and 2). Levels of EAAC1 and GLASTNo abnormalities have been identified in the cortical or
were below detection limits in spinal cords of normal andsubcortical structures of the brain.
G85R mice, although GLAST was detected in cerebellar
homogenates and EAAC1 in hippocampal homoge-
nates. Correlation of transporter activities and immu-Rapid, Nearly Synchronous Degeneration
and Death of Large Motor Neurons noblotting of brain has previously shown that all three
antibodies have comparable sensitivities in detectingFollowing Onset
To examine the progression of ventral motor neuron the corresponding transporters (Rothstein et al., 1994b;
1996). These findings indicate that GLT-1 is the majoraxonal degeneration, we counted the number of appar-
ently healthy axons and the number of axons actively glutamate transporter in spinal cord and that there is
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Figure 3. Lewy Body-Like Astrocytic Inclusions Strongly Immunoreactive for SOD1 Are Early Markers of Disease
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reduction in its abundance as disease progresses in the arises from the physical presence of the inclusion or
from aberrant chemistry mediated by the SOD1 in theseG85R mice.
aggregates remains unresolved. An additional key ques-
tion not yet resolved is whether the SOD1 in these inclu-Discussion
sions represents the mutant subunit, endogenous
SOD1, or a mixture of both. We have attempted to an-We have shown that low levels of accumulated human
G85R SOD1 (between 0.2 and 1.0 3 the level of endoge- swer this using peptide antibodies specific for human
or mouse SOD1; however, they have failed to detectnous SOD1) are sufficient to cause severe motor neuron
disease without altering the protein and activity levels the corresponding proteins by immunocytochemistry,
despite repeated attempts and their high sensitivity onof endogenous SOD1. This level of human FALS-linked
mutant SOD1 is z20-fold , the amount required to me- immunoblots. Since expression of wild-type SOD1 alone
does not form such aggregates even at 12 3 the normaldiate disease by two previously described human FALS-
linked mutants, G93A (Gurney et al., 1994) and G37R level, it must be that the mutant protein induces aggre-
gate formation. However, neither the level of endoge-(Wong et al., 1995), indicating that G85R is significantly
more toxic, at least in mice. Moreover, the most striking nous mouse protein nor its activity in whole tissue ex-
tracts is altered even at end stage, indicating that overallfinding in transgenic mice expressing human G85R
SOD1 is the presence of numerous inclusions in degradation and activity of endogenous mouse SOD1 is
not significantly affected by the presence of the mutantastrocytes that appear prior to similar inclusions in neu-
rons. By end stage, when there is a 2-fold elevation in subunit. Of course, as both activity and protein levels of
mouse and mutant SOD1 are measures of whole spinalSOD1 protein in whole spinal cord extracts and a 60%
loss of large axons, inclusions are approximately 10 3 cord, we cannot exclude the possibility that there are
regional differences in SOD1 activity and accumulation.more abundant in astrocytes than neurons, indicating
that for this mutation, astroglia are a major target of Indeed, the SOD1-containing inclusions, primarily in
astrocytes butalso in motor neurons, offer direct experi-SOD1-mediated damage. Both the dense core and the
periphery of both astrocytic and neuronal inclusions mental support for the possibility that toxicity of some
SOD1 mutants may arise from mutant-mediated aggre-show high levels of SOD1 immunoreactivity. While no
autopsy material is available for familial cases with the gation and the corresponding mislocalization of SOD1
(including local loss of activity). This cannot be the onlyG85R mutation (N. Siddique and T. Siddique, personal
communication), neuronal SOD1-positive inclusions affect of the mutants, however, since complete loss of
SOD1 does not result in motor neuron disease (Reaumehave been described in some familial ALS patients with
mutation A4V (Shibata et al., 1996), and inclusions with et al., 1996).
Central to understanding the mechanism of neuronalsimilar SOD1 immunoreactivity in astrocytes have also
been reported in a familial ALS patient with a 2 bp dele- death in SOD1-linked familial ALS is the identity of the
toxic property or properties that lead to familial ALS.tion in the 126th codon of SOD1 leading to a frameshift
and truncation of the final 27 amino acids (Kato et al., One hypothesis put forward by Beckman and colleagues
(Beckman et al., 1993) is that the mutant subunits unfold1996). However, the demonstration here that SOD1-con-
taining inclusions in astrocytes are early abnormalities slightly, allowing increased access of peroxynitrite
(formed spontaneously from nitricoxide [NO] and super-and increase markedly in abundance after disease onset
provides strong support for the view that at least some oxide anion [O22]) to the enzyme-bound copper, which
in turn uses peroxynitrite to nitrate tyrosine residues onof the familial ALS-linked SOD1 mutants mediate dis-
ease by direct affects on astrocytes, in both human and proteins. A second hypothesis holds that the mutants
catalyze the formation of hydroxyl radicals from hydro-murine disease.
Although it is not obvious how inclusions originate, gen peroxide via a process called the Fenton reaction.
Hydroxyl radicals have been proposed to damage athe finding that these inclusions contain abundant SOD1
polypeptides, both in the core and periphery, implicates variety of cellular targets including SOD1, mitochondrial
membranes (via lipid peroxidation), and glutamate trans-aberrant accumulation of mutant protein, perhaps as a
result of an altered conformation that resists the ubiqui- porters (via oxidation) (Pogun et al., 1994). In vitro, at
least two mutations can increase the rate of hydroxyltin-mediated degradation pathway. Whether toxicity
(A and B) Lewy body-like cytoplasmic inclusions in astrocytes, consisting of a pale periphery and dense central core seen by (B) H and E as
one of the earliest pathological findings in a 6-month-old transgenic mouse (line 148) expressing G85R SOD1.
(A) The astrocytic nature of the cells that contain these inclusions is demonstrated by the peripheral, halo-like staining with antibodies to
GFAP (arrow). Arrowhead points to a nucleus of an adjacent motor neuron.
(C) Individual inclusions (H and E, inset) from an end-stage G85R animal, and destaining–restaining with (C) antibodies to GFAP reveals that
the periphery of these inclusions are immunoreactive for GFAP. Open Arrow points to a reactive astrocyte. Arrowhead points to an adjacent
motor neuron nucleus.
(D and E) H and E view (D) of an end-stage G85R spinal cord revealing (arrows) two Lewy-body like inclusions. (E) Destaining and restaining
of the same section as in (D) using an antibody to NF-L demonstrates that both inclusions are not in neurons. Arrowhead in (D) and (E) points
to a motor neuron.
(F and G) H and E staining reveals an astrocytic inclusion and (arrowhead) a normal motor neuron in a spinal cord section from G85R (F) line
148 or (G) line 87 animals after clinical onset. Inset in F: the same astrocyte as in (F) after destaining and restaining with an antibody recognizing
human and mouse SOD1. Inset in G: the same astrocyte as in (G) after destaining and restaining with an antibody to ubiquitin. Scale bars: in
A, 25 mm; B, 5 mm; and C–G, 10 mm.
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Figure 4. Electron Microscopy Reveals That
the SOD1-Reactive Lewy Body-Like Inclu-
sions Are Intracellular with a Disorganized Fil-
amentous Core and Circumferential Interme-
diate Filaments
(A) An intracellular inclusion with a dense core
consisting of a heterogeneous mass of short
(200–300 nm long), disorganized filamentous
material. Scale bar, 25 nm.
(B) Higher magnification of the area high-
lighted in (A). Small granules and surrounding
filaments (together z20 nm in diameter) con-
tain entrapped organelles.
(C) The more linear array of 10 nm filaments
(presumably GFAP intermediate filaments) at
the periphery of the inclusion. Scale bars in
(B) and (C), 200 nm.
radical formation, probably due to increased availability riod of G85R-mediated disease offers strong support
for the idea that molecular targets exist within astrocytesof the active Cu21 site to H2O2 (Wiedau-Pazos et al.,
1996). However, there is as yet no in vivo support (in that can be damaged by mutant SOD1. Dysfunction of
astrocytes could have significant consequences. Thesehuman tissues or in mouse models) for either hypothe-
sis. Moreover, that mice expressing G85R SOD1 differ cells provide molecules (e.g., trophic factors and nutri-
ents, etc.) that crucial for neuronal viability (Oppenheimclinically (later onset plus rapid and synchronous motor
neuron loss after onset) and pathologically (numerous et al., 1988; Lin et al., 1993). Moreover, these cells influ-
ence the microenviroment in the neuropil through scav-astroglial inclusions and absence of vacuoles) from
G93A and G37R SOD1 mice may be explained by differ- enging of extracellular neurotransmitters, such as gluta-
mate. The primary mechanism for the inactivation ofences 1) in the toxic properties of the mutants, such as
preferential, conformation-dependent use of peroxide, glutamate is its removal from the extracellular space by
glutamate transporters. One of these, GLT-1, is foundperoxynitrite, or other abnormal substrates and 2) the
specific vulnerabilities of different cell types (i.e., glia or only in glia (Rothstein et al., 1994b). A second, GLAST,
was initially thought to be present in glia and neuronsneurons) to each mutant’s toxic effects.
That SOD1-mediated damage to the astrocytes is the but more recently has been argued to be only in glia
(Rothstein et al., 1996), while the third, EAAC1, is foundmost prominent early abnormality in the preclinical pe-
An SOD1 Mutant Causes Glial and Neuronal Abnormalities
335
Figure 5. SOD1 and Ubiquitin Immunoreactive Inclusions in Neuronal Cell Bodies and Processes in G85R Transgenic Mice Are Early Hallmarks
of Disease That Increase in Abundance at End-Stage Disease
(A and B) Early neuronal abnormalities in G85R transgenic animals consist of diffusely localized cytoplasmic aggregates that are immunoreactive
with (A) ubiquitin or (B) SOD1 antibodies. In both cases, these cytoplasmic aggregates display significantly more intense immunoreactivity
than that seen in normal, unaffected neurons (denoted by arrowheads).
(C–H) Neurons from G85R transgenic animals following clinical onset reveal intracellular inclusions distinguishable by ([C], [E], and [G]) H and
E staining in ([C], inset, and [E]) cell bodies and in ([C] and [G]) processes. Destaining and restaining of the same neurons with antibodies to
(D) SOD1, (F) ubiquitin, or (H) NF-L demonstrate that the core of the inclusions are intensely reactive with SOD1 antibodies, while only the
periphery is reactive with antibodies to ubiquitin or NF-L. (C), (D), (G), and (H): G85R line 148; (E) and (F): G85R line 87. Scale bar in A–H,
10 mm.
Experimental Proceduresonly in neurons (Rothstein et al., 1994b). We have shown
here that GLT-1 is the most abundant glutamate trans-
Construction of Transgenic Mice Expressing Mutantporter in spinal cords and that levels of it are decreased
G85R Human SOD1
in end-stage G85R mice, a finding that is strikingly simi- The G85R mutation was engineered into the human SOD1 gene (a 12
lar to that observed in patients with sporadic ALS kb EcoRI–BamHI genomic DNA fragment) by PCR/oligonucleotide
primer-directed mutagenesis strategy as described by Wong et al.(Rothstein et al., 1995). Moreover, loss of either glial
(1995), starting from a previously characterized plasmid, pHGSOD-transporter, GLT-1 or GLAST, via chronic intraventric-
SVneo (Epstein et al., 1987) encoding wild-type human SOD1.ular antisense oligonucleotide administration has been
Transgenic founder mice were identified by blotting of DNA isolated
shown to produce a progressive motor deficit in rats from mouse tail using a human SOD1 cDNA as a probe.
(Rothstein et al., 1996). Indeed, in these antisense exper-
iments, obvious motor deficits arose when GLT-1 levels
Quantitation of G85R SOD1 in Lines of Transgenic Micewere reduced by only 50%, a reduction similar to the loss
Whole spinal cords from transgenic and control mice were homoge-in GLT-1 arising during G85R SOD1-mediated disease.
nized in buffer containing 50 mM Tris, 150 mM NaCl, 5 mM EDTA,
Since impairments in the transport of glutamate from the 1% SDS, 1% NP40, and 1 mM each of leupeptin, pepstatin, and
neuropil in the ventral horn could render motor neurons chymostatin. Homogenates were sonicated for 20 s, boiled for 10
vulnerable to excitotoxicity, a plausible explanation for min, and clarified by centrifugation at 16,000 3 g, and supernatants
were transferred to new tubes. After determining the protein concen-the rapid, nearly synchronous axonal degeneration and
tration using a bicinchonic acid (BCA) protein assay (Pierce Chemi-neuronal loss at end stage (at a time that the mutant
cal Company, Rockford, Illinois), 70 mg of total protein were loadedprotein increases in overall abundance) is that G85R-
on 15% polyacrylamide gels, electrophoresed, and transferred to
induced damage to astrocytes, necessary for the viabil- nitrocellulose filters (Lopata and Cleveland, 1987). Immunoblots
ity of neurons, mediates the rapid spread of disease were reacted with polyclonal antipeptide antibodies (CYASGEPVVL
SGQIT corresponding to residues 24–36 from mouse SOD1 or CESNafter onset.
Neuron
336
Figure 6. Rapid Degeneration and Loss of
Large Motor Axons in Ventral Roots of G85R
SOD1 Mice Beginning at Onset of Clinical
Signs
(A and B) Percentage of (A) surviving (both
healthy and degenerating) large (.5 mm) and
small caliber axons in L4 ventral roots from
G85R, line 148 transgenic mice measured at
ages prior to clinical symptoms (3.5–6.5 M),
at onset of clinical signs, and at end stage.
A dramatic loss of large caliber axons is seen
beginning with disease onset; small caliber
axons are unaffected at all ages.
(B) Percentage of remaining large axons ac-
tively degenerating. Nodegeneration was ob-
served in small axons.
(C–E) Representative images of ventral roots
from (C) a 4.5-month-old animal prior to onset
of pathology, (D) an 8-month-old animal at
clinical onset, and (E) an end-stage (8.5-
month-old) animal. Scale bar, 12 mm.
GPVKVWGSIK corresponding to residues 24–36 from human SOD1) nitrocellulose, and immunoblotted with an antibody specific for hu-
or an antipeptide antibody (Pardo et al., 1995) generated against a man SOD1.
sequence identical in human and mouse SOD1 (CYDDLGKGGNEE
STK corresponding to residues 124–136). Bound primary antibody Measurement of SOD1 Activity
was detected with 125I-labeled protein A. Quantitation was achieved The spinal cords from control and transgenic mice were homoge-
by immunoblotting a dilution series of known amounts of purified nized in buffer containing 20 mM Tris–HCl (pH 7.2), 1 mM EDTA,
human erythrocyte SOD1 (Sigma, St. Louis) in parallel. Signals were and 1% Triton X-100. After centrifugation at 10,000 3 g for 5 min,
quantified using a Molecular Dynamics Phosphorimager (Sunnyvale, the supernatant was electrophoresed on a 7.5% polyacrylamide
California). gel, and SOD1 activities were determined as previously reported
(Beauchamp and Fridovich, 1971).
Detection of Blood SOD1
Blood from nontransgenic mice, mice expressing wild-type human
Measurement of Levels of Glutamate TransportersSOD1, and G85R transgenic mice was hemolyzed, extracted with
GLT-1, GLAST, and EEAC1ethanol and chloroform (L’Abbe and Fischer, 1990), and clarified by
Extracts of whole spinal cord from control and transgenic micecentrifugation at 10,000 3 g. The supernatant (red blood cell lysate)
was electrophoresed on a 15% polyacrylamide gel, transferred onto were prepared as described above and electrophoresed on 7.5%
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peroxide, rinsed in phosphate-buffered saline, and incubated over-
night in the primary antibody. Immunoreactivity was visualized with
diaminobenzidine, and sections were counterstained with hematox-
ylin. For characterization of inclusion bodies, H and E–stained sec-
tions of spinal cords from end-stage animals were examined and
photographed by light microscopy. Coverslips were removed, slides
were rinsed in xylene, 100%, 95%, and 70% alcohol, decolorized
with 1% HCl in 70% ethanol for a few minutes, and stained by
standard immunocytochemical methods.
Electron Microscopy
Spinal cords and roots were dissected from transcardially perfused
animals and postfixed in 4% paraformaldehyde and 1% gluteralde-
hyde. Subsequently, tissues were incubated in 2% osmiumtetroxide
in 0.05 M cacodylate for 3.5 hr, washed, dehydrated, and embedded
in Epon–Araldite resin (Ernest F. Fullam, Inc., Latham, New York).
Thick (0.75 mm) sections stained with toludine blue were examined
by light microscopy, while thin (70 nm) sections were stained with
lead citrate–uranyl acetate and examined by electron microscopy.
Quantitation of Motor Neuron Degeneration
Large (.5 mm diameter) and small (,5 mm diameter) axons were
counted in cross sections of L4 ventral roots from transgenic mice
at 3.5, 4.5,and 6.5 months of age, as well as transgenic mice showing
the first signs of hindlimb weakness and at end-stage disease. The
number of surviving axons was determined as a percentage of the
total number of large or small axons in an average of five control
mice. The number of degenerating axons was determined as a per-
centage of the total number of surviving (both healthy and degener-
ating) axons. Two animals were used for each time point.
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